Mucocutaneous manifestations in children hospitalized with COVID-19 - 07/06/21
, Montserrat Nieto-Moro, MD b, Jose Antonio Alonso-Cadenas, MD a, Juan Añon-Hidalgo, MD c, Angela Hernandez-Martin, MD d, Esther Perez-Suarez, MD a, Isabel Colmenero-Blanco, MD d, Maria Isabel Iglesias-Bouza, MD b, Julia Cano-Fernandez, MD c, Ana Mateos-Mayo, MD d, Antonio Torrelo, MD d
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Cutaneous manifestations in hospitalized children with SARS-CoV-2 have not been studied systematically.
Objective |
To describe the mucocutaneous involvement in pediatric patients with COVID-19 admitted to a pediatric institution in Madrid (Spain), located in a zone reporting among the highest prevalence of COVID-19 in Europe.
Methods |
A descriptive, analytical study was conducted on a series of 50 children hospitalized with COVID-19 between March 1, 2020, and November 30, 2020.
Results |
Twenty-one patients presented with mucocutaneous symptoms: 18 patients with macular and/or papular exanthem, 17 with conjunctival hyperemia, and 9 with red cracked lips or strawberry tongue. Eighteen patients fulfilled criteria for multisystem inflammatory syndrome in children. Patients with mucocutaneous involvement tended to be older and presented to the emergency department with poor general status and extreme tachycardia, higher C-reactive protein and D-dimer levels, and lower lymphocyte counts than patients without skin signs. Mucocutaneous manifestations pose a higher risk of admission to the pediatric intensive care unit (odds ratio, 10.24; 95% confidence interval, 2.23-46.88; P = .003).
Conclusions |
Children hospitalized with COVID-19 frequently had mucocutaneous involvement, with most symptoms fulfilling criteria for multisystem inflammatory syndrome in children. Patients with an exanthem or conjunctival hyperemia at admission have a higher probability of pediatric intensive care admission than patients without mucocutaneous symptoms.
Le texte complet de cet article est disponible en PDF.Key words : COVID-19, pediatric dermatology, multisystem inflammatory syndrome, SARS-CoV-2
Abbreviations used : MIS-C, PICU, RT-PCR
Plan
| Funding sources: None. |
|
| IRB approval status: Approval was provided by the Ethics Committee and Board of the Hospital Infantil Universitario Niño Jesús. Standard informed consent was obtained to record images. |
Vol 85 - N° 1
P. 88-94 - juillet 2021 Retour au numéro
Article précédent
- The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study
- Khalaf Kridin, Yochai Schonmann, Orly Weinstein, Enno Schmidt, Ralf J. Ludwig, Arnon D. Cohen
- Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study
- Aditya K. Gupta, Maria S. Surprenant, Steven E. Kempers, David M. Pariser, Kjell Rensfeldt, Amir Tavakkol
Bienvenue sur EM-consulte, la référence des professionnels de santé.